Anti-Mouse CD279 (PD-1) (Clone RMP1-14) – Purified

Pricing & Details

Product No.C2857
Clone
RMP1-14
Protein
PD-1
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
Programmed Death-1, CD279, PD1
Isotype
Rat
IgG2a κ
Applications
FC
,
IHC FFPE
,
WB
Prod No.
Size
Price
Avail.
Qty
Add to cart
C2857-0.5 mg
0.5 mg
$107.00
In stock
Max:
Min: 1
Step: 1
Bulk quantities available. Contact us for pricing.

Data

Antibody Details

Product Details

Reactivity Species
Mouse
Host Species
Rat
Immunogen
Subset of double negative thymocytes, activated T and B cells
Product Concentration
0.5 mg/ml
Formulation
This purified antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Storage and Handling
This purified antibody is stable when stored at 2-8°C. Do not freeze.
Country of Origin
USA
Shipping
Next Day 2-8°C
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
Clone RMP1-14 recognizes an epitope on mouse PD-1.
Antigen Distribution
PD-1 is expressed on a subset of CD4-CD8- thymocytes, and on activated T and B cells.
Background
PD-1 is a 50-55 kD member of the B7 Ig superfamily. PD-1 is also a member of the extended CD28/CTLA-4 family of T cell regulators and is suspected to play a role in lymphocyte clonal selection and peripheral tolerance. The ligands of PD-1 are PD-L1 and PD-L2, and are also members of the B7 Ig superfamily. PD-1 and its ligands negatively regulate immune responses. PD-L1, or B7-Homolog 1, is a 40 kD type I transmembrane protein that has been reported to costimulate T cell growth and cytokine production. The interaction of PD-1 with its ligand PD-L1 is critical in the inhibition of T cell responses that include T cell proliferation and cytokine production. PD-L1 has increased expression in several cancers. Inhibition of the interaction between PD-1 and PD-L1 can serve as an immune checkpoint blockade by improving T-cell responses In vitro and mediating preclinical antitumor activity. Within the field of checkpoint inhibition, combination therapy using anti-PD1 in conjunction with anti-CTLA4 has significant therapeutic potential for tumor treatments. PD-L2 is a 25 kD type I transmembrane ligand of PD-1. Via PD-1, PD-L2 can serve as a co-inhibitor of T cell functions. Regulation of T cell responses, including enhanced T cell proliferation and cytokine production, can result from mAbs that block the PD-L2 and PD-1 interaction.

Antigen Details

Protein
Ligand/Receptor
PD-L1 (B7-H1), PD-L2
Function
Lymphocyte clonal selection, peripheral tolerance
PubMed
NCBI Gene Bank ID
Research Area
Apoptosis
.
Cancer
.
Cell Biology
.
Cell Death
.
Immunology
.
Inhibitory Molecules
.
Tumor Suppressors

References & Citations

1. Schreiber, RD. et al. (2017) Cancer Immunol Res. 5(2):106-117.
2. Honjo, T. et al. (1992) EMBO J. 11:3887.
Flow Cytometry
IHC
General Western Blot Protocol

Formats Available

Products are for research use only. Not for use in diagnostic or therapeutic procedures.